MX2014006990A - Tratamiento para diabetes tipo i y tipo ii. - Google Patents

Tratamiento para diabetes tipo i y tipo ii.

Info

Publication number
MX2014006990A
MX2014006990A MX2014006990A MX2014006990A MX2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A
Authority
MX
Mexico
Prior art keywords
type
diabetes
treatment
mammal
effective amount
Prior art date
Application number
MX2014006990A
Other languages
English (en)
Other versions
MX359171B (es
Inventor
Andrew G Reaume
Michael S Saporito
Alexander R Ochman
Original Assignee
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc filed Critical Melior Pharmaceuticals I Inc
Publication of MX2014006990A publication Critical patent/MX2014006990A/es
Publication of MX359171B publication Critical patent/MX359171B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar diabetes tipo I o tipo II en un mamífero mediante la administración de una cantidad eficaz de insulina y una cantidad eficaz de un compuesto de fenoxipirimidinona al mamífero en necesidad de este tratamiento, y formulaciones para llevar a cabo los métodos.
MX2014006990A 2011-12-12 2012-12-12 Tratamiento para diabetes tipo i y tipo ii. MX359171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569496P 2011-12-12 2011-12-12
PCT/US2012/069072 WO2013090319A2 (en) 2011-12-12 2012-12-12 Treatment of type i and type ii diabetes

Publications (2)

Publication Number Publication Date
MX2014006990A true MX2014006990A (es) 2015-02-05
MX359171B MX359171B (es) 2018-09-18

Family

ID=48613352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006990A MX359171B (es) 2011-12-12 2012-12-12 Tratamiento para diabetes tipo i y tipo ii.

Country Status (15)

Country Link
US (2) US20150190396A1 (es)
EP (1) EP2790704B1 (es)
JP (1) JP6152387B2 (es)
KR (1) KR102069395B1 (es)
CN (2) CN107007608B (es)
AU (2) AU2012352480A1 (es)
BR (1) BR112014014289A8 (es)
CA (1) CA2859156C (es)
HK (1) HK1202819A1 (es)
IL (1) IL233004B (es)
MX (1) MX359171B (es)
RU (1) RU2646475C2 (es)
SG (2) SG11201403207WA (es)
WO (1) WO2013090319A2 (es)
ZA (1) ZA201404738B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10863264B2 (en) 2017-01-23 2020-12-08 David Sampson Vibration inducing tactile apparatus
US11254645B2 (en) 2018-01-11 2022-02-22 Bukwang Pharmaceutical Co., Ltd. Method for preparing tolimidone on large scale

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
NZ565955A (en) * 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
RU2316339C1 (ru) * 2006-09-13 2008-02-10 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата инсулина для перорального применения
KR20100014480A (ko) * 2007-02-20 2010-02-10 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성제의 확인 방법
NZ579288A (en) * 2007-07-23 2012-06-29 Melior Discovery Inc Methods of activating irs-1 and akt
PT2355829E (pt) * 2008-12-12 2015-02-20 Poxel S A S Combinação de insulina com derivados de triazina e suas utilizações para o tratar diabetes
US20130158055A1 (en) * 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
NZ758966A (en) * 2017-04-10 2024-08-30 Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Treatment of adipocytes

Also Published As

Publication number Publication date
JP2015513310A (ja) 2015-05-07
SG11201403207WA (en) 2014-09-26
CA2859156C (en) 2020-10-06
CN104271140A (zh) 2015-01-07
BR112014014289A2 (pt) 2017-06-13
KR102069395B1 (ko) 2020-01-22
EP2790704A4 (en) 2015-09-02
HK1202819A1 (en) 2015-10-09
US20200215068A1 (en) 2020-07-09
RU2014128528A (ru) 2016-02-10
US20150190396A1 (en) 2015-07-09
RU2646475C2 (ru) 2018-03-05
KR20140107416A (ko) 2014-09-04
CN107007608A (zh) 2017-08-04
NZ626495A (en) 2016-03-31
CA2859156A1 (en) 2013-06-20
IL233004A0 (en) 2014-07-31
CN107007608B (zh) 2021-04-23
IL233004B (en) 2020-01-30
EP2790704B1 (en) 2019-04-03
BR112014014289A8 (pt) 2017-06-13
WO2013090319A2 (en) 2013-06-20
SG10201604828QA (en) 2016-07-28
JP6152387B2 (ja) 2017-06-21
AU2017204652A1 (en) 2017-07-27
EP2790704A2 (en) 2014-10-22
AU2012352480A1 (en) 2014-07-17
WO2013090319A3 (en) 2014-12-04
MX359171B (es) 2018-09-18
CN104271140B (zh) 2016-11-23
AU2017204652B2 (en) 2018-08-16
ZA201404738B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
PH12014501702A1 (en) Imidazopyrrolidinone compounds
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2011328009A8 (en) Compounds and methods for treating pain
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
MX2013011922A (es) Compuestos de benceno substituido.
EA201500019A1 (ru) Способ лечения gd2-положительного рака
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2013012785A (es) Tratamiento del mieloma multiple.
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
IN2014DN03464A (es)
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
PH12014502065A1 (en) Vesicular formulations
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
MX2016002307A (es) Tratamiento para el cancer.
AU2012240388A8 (en) Treatment regimens
MX2014006255A (es) Tratamientos neurologiocos con metaloporfirina.
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

Legal Events

Date Code Title Description
FG Grant or registration